Rinsho Seikei Geka Volume 42, Issue 2 (February 2007)

Therapeutic and Preventive Effect of Methylene Blue against Ifosfamide Encephalopathy during Chemotherapy for Musculoskeletal Sarcomas Takahiro Tajino 1 , Shin-ichi Kikuchi 1 , Shin-ichi Konno 1 , Hitoshi Yamada 1 , Akira Takeda 2 1Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine 2Department of Orthopaedic Surgery, Southern Tohoku General Hospital Keyword: ifosfamide(イホスファミド) , encephalopathy(脳症) , methylene blue(メチレンブルー) pp.107-114
Published Date 2007/2/25
DOI https://doi.org/10.11477/mf.1408100847
  • Abstract
  • Look Inside
  • Reference

 We investigated the incidence, severity, and risk factors for ifosfamide encephalopathy in patients being treated for bone and soft tissue sarcoma and assessed the therapeutic and preventive effect of methylene blue against this adverse reaction. Ifosfamide encephalopathy developed in 16(40%) of 40 cases and in 28 (23.3%)of 120 courses of treatment. The most common symptoms of encephalopathy were“somnolence”,“confusion”, and“mood alteration-agitation”. Severe encephalopathy had occurred in the patients treated with ifosfamide doses of 9g/m2 or more. Previous cisplatin therapy was a significant risk factor. There was no clear therapeutic effect of methylene blue on the encephalopathy, but preventive efficacy was suggested.

Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.


42巻2号 (2007年2月)
電子版ISSN 1882-1286 印刷版ISSN 0557-0433 医学書院